Matt  Davidson net worth and biography

Matt Davidson Biography and Net Worth

Major Shareholder of Verrica Pharmaceuticals

Matt Davidson is the co-founder and former CEO of Verrica Pharmaceuticals.

Davidson founded Verrica in 2013a year after he received his Ph.Dand led the company as CEO and chairman as they developed dermatology therapeutics for skin diseases that required medical interventions. Their core technologies resulted in six patents. 

He helped guide Verrica from the preclinical stage to its IPO in 2018, raising $75 million to push several projects to clinical development. In his time with the company, Davidson raised over $100 million from various angel, seed, and series A and B financing. He turned the CEO reins over to Novartis veteran, Ted White, in 2018, and he formally stepped away from Verrica in 2020 to pursue other opportunities. 

Davidson went on to found biotechnology company, MGD Ventures, in 2018 and pharmaceutical company, Azora Therapeutics, in 2019. MGD Ventures invests in and advises life science companies with clinically derisked assets for unmet clinical needs. Companies they have advised include VioSera Therapeutics (resistance suppression), August Therapeutics (eating disorders and obesity) and Palmm (hyperhidrosis). 

He was also a scientist at Applied Immunology (acquired by Precision for Medicine) in 2013 and a research technician at the Howard Hughes Medical Institute from 2006 to 2007. 

Previously, Davidson founded, developed and commercialized Think Gum, a “brain-boosting” chewing gum that enhances memory. Think Gum was the winner of the first Stanford University Student Enterprises Ventures competition (now Start-X) in 2007, and it was acquired by Think Products in 2019. 

Davidson holds a Ph.D in immunology from the Stanford University School of Medicine and a B.A. in molecular and cellular biology from the University of California, Berkeley. He is also a graduate of Stanford University Graduate School of Business’ Ignite Program.

What is Matt Davidson's net worth?

The estimated net worth of Matt Davidson is at least $1.79 million as of August 29th, 2019. Mr. Davidson owns 2,577,681 shares of Verrica Pharmaceuticals stock worth more than $1,789,426 as of December 22nd. This net worth approximation does not reflect any other investments that Mr. Davidson may own. Learn More about Matt Davidson's net worth.

How do I contact Matt Davidson?

The corporate mailing address for Mr. Davidson and other Verrica Pharmaceuticals executives is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. Verrica Pharmaceuticals can also be reached via phone at (434) 453-3300 and via email at [email protected]. Learn More on Matt Davidson's contact information.

Has Matt Davidson been buying or selling shares of Verrica Pharmaceuticals?

Matt Davidson has not been actively trading shares of Verrica Pharmaceuticals in the last ninety days. Most recently, Matt Davidson sold 19,314 shares of the business's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $10.89, for a transaction totalling $210,329.46. Learn More on Matt Davidson's trading history.

Who are Verrica Pharmaceuticals' active insiders?

Verrica Pharmaceuticals' insider roster includes Matt Davidson (Major Shareholder), A. Davis (CFO), Christopher Hayes (Insider), Paul Manning (Director), and Ted White (CEO). Learn More on Verrica Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Verrica Pharmaceuticals?

During the last year, Verrica Pharmaceuticals insiders bought shares 2 times. They purchased a total of 180,768 shares worth more than $1,247,592.76. During the last year, insiders at the sold shares 2 times. They sold a total of 57,930 shares worth more than $408,985.80. The most recent insider tranaction occured on July, 22nd when CEO Ted White sold 32,469 shares worth more than $229,231.14. Insiders at Verrica Pharmaceuticals own 42.6% of the company. Learn More about insider trades at Verrica Pharmaceuticals.

Information on this page was last updated on 7/22/2024.

Matt Davidson Insider Trading History at Verrica Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/9/2019Sell19,314$10.89$210,329.46
8/29/2019Sell2,688$10.16$27,310.082,577,681View SEC Filing Icon  
8/9/2019Sell6,313$10.49$66,223.37View SEC Filing Icon  
8/6/2019Sell6,250$10.54$65,875.00View SEC Filing Icon  
8/1/2019Sell10,338$11.92$123,228.96View SEC Filing Icon  
7/29/2019Sell12,058$11.40$137,461.20View SEC Filing Icon  
7/24/2019Sell2,802$10.24$28,692.48View SEC Filing Icon  
7/19/2019Sell10,800$10.33$111,564.00View SEC Filing Icon  
7/16/2019Sell10,490$10.93$114,655.70View SEC Filing Icon  
7/11/2019Sell13,212$11.58$152,994.96View SEC Filing Icon  
7/8/2019Sell12,529$11.27$141,201.83View SEC Filing Icon  
7/2/2019Sell33,521$11.63$389,849.23View SEC Filing Icon  
6/25/2019Sell210$10.04$2,108.40View SEC Filing Icon  
6/13/2019Sell2,131$9.65$20,564.15View SEC Filing Icon  
6/11/2019Sell4,345$8.49$36,889.05View SEC Filing Icon  
6/6/2019Sell5,507$7.27$40,035.89View SEC Filing Icon  
6/3/2019Sell4,110$7.36$30,249.60View SEC Filing Icon  
5/29/2019Sell2,100$8.41$17,661.00View SEC Filing Icon  
5/23/2019Sell2,422$8.80$21,313.60View SEC Filing Icon  
5/20/2019Sell1,800$8.95$16,110.00View SEC Filing Icon  
5/15/2019Sell6,973$9.11$63,524.03View SEC Filing Icon  
5/10/2019Sell3,356$9.21$30,908.76View SEC Filing Icon  
5/7/2019Sell3,900$9.28$36,192.00View SEC Filing Icon  
5/2/2019Sell1,768$9.86$17,432.48View SEC Filing Icon  
4/29/2019Sell3,302$9.90$32,689.80View SEC Filing Icon  
4/24/2019Sell9,203$9.92$91,293.76View SEC Filing Icon  
4/18/2019Sell3,516$10.54$37,058.64View SEC Filing Icon  
4/16/2019Sell3,193$10.39$33,175.27View SEC Filing Icon  
4/11/2019Sell18,850$10.16$191,516.00View SEC Filing Icon  
4/8/2019Sell12,385$10.67$132,147.95View SEC Filing Icon  
4/3/2019Sell13,436$10.37$139,331.32View SEC Filing Icon  
3/26/2019Sell13,667$11.50$157,170.50View SEC Filing Icon  
3/21/2019Sell7,920$12.27$97,178.40View SEC Filing Icon  
3/18/2019Sell11,626$12.26$142,534.76View SEC Filing Icon  
3/13/2019Sell25,045$11.55$289,269.75View SEC Filing Icon  
3/8/2019Sell20,558$11.72$240,939.76View SEC Filing Icon  
3/5/2019Sell25,830$12.46$321,841.80View SEC Filing Icon  
2/28/2019Sell14,305$11.26$161,074.30View SEC Filing Icon  
2/25/2019Sell13,071$11.05$144,434.55View SEC Filing Icon  
2/20/2019Sell13,544$11.33$153,453.52View SEC Filing Icon  
2/14/2019Sell13,191$12.36$163,040.76View SEC Filing Icon  
2/11/2019Sell13,057$13.53$176,661.21View SEC Filing Icon  
2/6/2019Sell15,859$12.93$205,056.87View SEC Filing Icon  
2/1/2019Sell10,298$11.95$123,061.10View SEC Filing Icon  
1/29/2019Sell10,220$10.94$111,806.80View SEC Filing Icon  
1/24/2019Sell3,100$10.12$31,372.00View SEC Filing Icon  
1/18/2019Sell5,765$10.26$59,148.90View SEC Filing Icon  
1/15/2019Sell8,019$10.53$84,440.07View SEC Filing Icon  
1/10/2019Sell15,802$10.87$171,767.74View SEC Filing Icon  
1/7/2019Sell33,276$9.80$326,104.80View SEC Filing Icon  
1/2/2019Sell1,000$8.25$8,250.00View SEC Filing Icon  
12/27/2018Sell4,100$8.02$32,882.00View SEC Filing Icon  
12/21/2018Sell12,439$7.35$91,426.65View SEC Filing Icon  
12/18/2018Sell4,215$9.57$40,337.55View SEC Filing Icon  
See Full Table

Matt Davidson Buying and Selling Activity at Verrica Pharmaceuticals

This chart shows Matt Davidson's buying and selling at Verrica Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verrica Pharmaceuticals Company Overview

Verrica Pharmaceuticals logo
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Read More

Today's Range

Now: $0.69
Low: $0.65
High: $0.74

50 Day Range

MA: $1.11
Low: $0.64
High: $1.68

2 Week Range

Now: $0.69
Low: $0.61
High: $11.41

Volume

1,536,957 shs

Average Volume

498,475 shs

Market Capitalization

$31.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4